Work

Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial

Year: 2025

Type: article

Study design: Clinical Trial

Source: The Lancet HIV

DOI: 10.1016/s2352-3018(25)00002-5

Authors: Ethel D Weld, Trevor Beattie, Jayajothi Moodley, Manasa Mapendere, Isadora Salles, Belén P Solans, Bareng A S Nonyane, Lubbe Wiesner, Tanya Nielson, Vinodh A Edward, Violet Chihota, Radojka M Savic, Kelly E Dooley, Richard E Chaisson, Gavin J Churchyard

Institutions: Johns Hopkins University, Johns Hopkins Medicine, Utrecht University, Aurum Institute, University of California, San Francisco, University of Cape Town, Vanderbilt University Medical Center, University of KwaZulu-Natal, University of the Witwatersrand, Vanderbilt University

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: ViiV Healthcare, National Institute of Allergy and Infectious Diseases

Awards: Optimizing the Use of Long-Acting Antiretrovirals for Youth Living withHIV, The Johns Hopkins Center for AIDS Research (JHU CFAR), Mentoring Investigators in HIV and Tuberculosis Therapeutics Research

OpenAlex ID: W4410197058

FWCI: 6.866

Cites: 19

Cited by: 9

Related to: 10